Offene, multizentrische, nicht-randomisierte Phase II Studie:
Dosiseskalation von Zevalin und zeitnahe Applikation der Hochdosischemotherapie BEAM gefolgt von autologer Stammzelltransplantation zur Behandlung von refraktären und rezidivierten aggressiven Non-Hodgkin-Lymphomen.
Kurztitel: esc Z-BEAM
Studiennummer: DSHNHL 2004-R4
EudraCT-Nr. 2004-003801-26

RitZ-Studie (Phase III) zur Bewertung einer 90Y ibritumomab tiuxetan (Zevalin®)-Konsolidierung und Rituximab-Erhaltung im Vergleich zu einer alleinigen Rituximab-Erhaltung in Patienten mit rezidiviertem follikulären Lymphom mit Ansprechen auf eine Immun-Chemotherapie. Phase III Studie
EudraCT-Nr. 2007-003199-20

HD18 für fortgeschrittene Stadien. Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms: Therapiestratifizierung mittels FDG-PET. Prospektiv, multicenter, randomisiert, Phase III.
EudraCT-Nr. 2007-003187-22

Intensivierung der Konditionierung vor allogener Stammzelltransplantation durch Radioimmunkonjugate bei Patienten mit Hochrisiko – Akuter myeloischer Leukämie
EudraCT-Nr. -

Phase III Studie einer Induktionstherapie mit Pemetrexed plus Cosplatin gefolgt von einer randomisierten, doppeltblinden,placebo-kontrollierten Erhaltungstherapie mit Pemetrexed plus Best Supportive Care vs. Placebo plus BSC bei fortgeschrittenem Non-Sqamous NSCLC. A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Immediately Following Induction Treatment With Pemetrexed + Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer.
EudraCT-Nr. 2008-002155-24

A Randomized Trial of Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Have Failed First-Line Sunitinib Therapy
EudraCT-Nr. -

Einsatz von Y-90-markierten Antikörpern zur Intensivierung der Konditionierung bei Patienten mit hämatologischen Neoplasien und hohem Rezidivrisiko
EudraCT-Nr. -

Improvement of Outcome and Reduction of Toxicity in Elderly Patients with CD20+ Aggressive B-Cell Lymphoma by an Optimised Schedule of the Monoclonal Antibody Rituximab, Substitution of Conventional by Liposomal Vincristine, and FDG-PET based Reduction of Therapy. Short title: OPTIMAL>60 DSHNHL 2009-1
Eudra-CT: 2010-019587-36

 

A multicentre, phase III, open label, randomized study in previously untreated patients with advanced indolent non-Hodgkin's lymphoma evaluating the benefit of GA101 (RO5072759) + chemotherapy compared to Rituximab + chemotherapy followed by GA101 or Rituximab maintenance therapy in responders.
Eudra-CT: 2010-024132-41

 

A randomized, open-label, multi-center phase II study to compare AUY922 with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of chemotherapy
Eudra-CT: 2009-015407-47

A phase IA/II, multi-center, open-label study of HCD122 administered intravenously once weekly for four weeks in adult patients with advanced non-Hodgkin’s or Hodgkin’s lymphoma who have progressed after at least two prior therapies
Eudra-CT: 2007-004888-22

Ofatumumab versus Rituximab Salvage Chemoimmunotherapy followed by ASCT in Relapsed or Refractory DLBCL
Eudra-CT: 2009-009256-20

An open-label, randomized, multi-center, Phase III study to compare the safety and efficacy of TKI258 versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies
Eudra-CT: 2009-015459-25

A Multinational Phase 3, Randomized, Double-Blind, Placebo Controlled Efficacy and Safety Study of Oral MDV3100 in Chemotherapy Naïve Patients with Progressive Metastatic Prostate Cancer Who Have Failed Androgen Deprivation Therapy
Eudra-CT: 2010-020821-41

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK 700) Plus Prednisone With Placebo Plus Prednisone in Patients With Chemotherapy Naïve Metastatic Castration-Resistant Prostate Cancer
EudraCT: 2010-018661-35

A Phase 3, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or Following Docetaxel-based Therapy
EudraCT:  2010-018662-23

A phase I, multicenter, open-label dose escalation study of LDK378, administered orally in adult patients with tumors characterized by genetic abnormalities in anaplastic lymphoma kinase (ALK)
EudraCT:  2010-019827-70

A Randomized Double-Blind Phase 3 Trial Comparing Docetaxel Combined with Dasatinib to Docetaxel Combined with Placebo in Castration-Resistant Prostate Cancer (CA180-227)
EudraCT:  2008-002158-40

A Phase II multi-center, non-randomized, open-label study of TKI258 in patients with either FGFR3 mutated or FGFR3 wild type advanced urothelial carcinoma
EudraCT:  2008-005870-11

GSK 2132231A Antigen-Specific Cancer Immunotherapeutic as adjuvant therapy in patients with resected melanoma: Doppelblinde, randomisierte, Placebo-kontrollierte Studie der Phase III zur Beurteilung der Wirksamkeit eines recMAGE-A3 + AS15 ASCI als adjuvante Therapie bei Patienten mit MAGE-A3- positivem reseziertem Melanom im Stadium III
EudraCT:  2008-002447-16

Comparison of dosimetry following preparation with either rhTSH or after withdrawal of thyroid hormone suppression therapy in patients with metastatic or locally advanced differentiated thyroid cancer
EudraCT: 

gepunktete blaue Linie 1000px breit